Pancreatic adenosquamous carcinoma with 7‐year survival: A case report and literature review

Matsubayashi, Hiroyuki; Matsunaga, Kazuya; Uesaka, Katsuhiko; Kanemoto, Hideyuki; Ito, Ichiro; Asakura, Hirofumi; Yagishita, Atsushi; Ono, Hiroyuki

doi:10.1111/1751-2980.12018

Cited by 7 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IHC positivity for pancreatic adenocarcinoma includes CK7, CK20, mesothelin, cancer antigen 125 (CA-125), and lysozyme [18,33] . The KI-67 index for one patient with ASCP with approximately a 70%-80% squamous carcinoma component was 33% [32] . As in pancreatic adenocarcinoma, KRAS mutations have also been observed in ASCP [18,27,31,34] .…”

Section: Pathologymentioning

confidence: 93%

“…Some have proposed that presence of any squamous cell carcinoma component in a pancreatic tumor should classify the cancer as adenosquamous [16,26,31] . Prior immunohistochemistry (IHC) analysis on patients with adenosquamous carcinoma have shown the cancer to be positive for cytokeratin (CK) 5/6, CK 7, and p63 and negative for CK 20, p16, and p53 [18,32] . IHC positivity for pancreatic adenocarcinoma includes CK7, CK20, mesothelin, cancer antigen 125 (CA-125), and lysozyme [18,33] .…”

Section: Pathologymentioning

confidence: 99%

See 1 more Smart Citation

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review

Borazanci

Millis

Korn

et al. 2015

WJGO

View full text Add to dashboard Cite

Adenosquamous carcinoma of the pancreas (ASCP) is a rare entity. Like adenocarcinoma of the pancreas, overall survival is poor. Characteristics of ASCP include central tumor necrosis, along with osteoclasts and hypercalcemia. Various theories exist as to why this histological subtype exists, as normal pancreas tissue has no benign squamous epithelium. Due to the rarity of this disease, limited molecular analysis has been performed, and those reports indicate unique molecular features of ASCP. In this paper, we characterize 23 patients diagnosed with ASCP through molecular profiling using immunohistochemistry staining, fluorescent in situ hybridization, chromogenic in situ hybridization, and gene sequencing, Additionally, we provide a comprehensive literature review of what is known to date of ASCP. Molecular characterization revealed overexpression in MRP1 (80%), MGMT (79%), TOP2A (75), RRM1 (42%), TOPO1 (42%), PTEN (45%), CMET (40%), and C-KIT (10%) among others. One hundred percent of samples tested were positive for KRAS mutations. This analysis shows heretofore unsuspected leads to be considered

show abstract

Section: Pathologymentioning

confidence: 93%

Section: Pathologymentioning

confidence: 99%

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review

Borazanci

Millis

Korn

et al. 2015

WJGO

View full text Add to dashboard Cite

show abstract

“…Demographic, tumor resection specimen, and treatment characteristics were obtained from the electronic medical record and/or paper chart for each patient. Additional data were obtained in regard to potential prognostic factors identified in previously published reports (4)(5)(6)(7)(8)(10)(11)(12)(13)(14)(15)(18)(19)(20). Patient-specific variables included age, sex, and ECOG performance status.…”

Section: Data Collectionmentioning

confidence: 99%

Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.

Wild

Dholakia

Fan

et al. 2013

JCO

View full text Add to dashboard Cite

e15028 Background: Pancreatic adenosquamous carcinoma (PASC) is a rare morphological subtype of pancreatic adenocarcinoma. PASC accounts for only 1-4% of exocrine pancreatic cancers and carries a particularly poor prognosis. Due to the rarity of PASC, studies of therapies specifically targeting this histopathologic entity are exceedingly limited. Based on efficacy exhibited by platinum agents against squamous carcinoma of other body sites, addition of these agents to adjuvant regimens may benefit patients with PASC. This retrospective study was performed among the largest series of patients with PASC identified to date in order to determine whether addition of platinum agents improves survival. Methods: Records of all patients who underwent pancreatic resection at our institution from 1986-2012 were reviewed to identify those with PASC. Demographic, surgical, pathologic, adjuvant therapy, and survival data were collected. Patients were divided into non-platinum (NPG) and platinum (PG) groups based on whether or not they received a platinum agent as part of adjuvant therapy. Results: In total, 62 patients with PASC were identified among 5,627 cases (1.1%). Fourteen patients received a platinum agent in the adjuvant setting (PG), while 48 did not (NPG). These two groups were comparable in regard to median age (65 vs. 69 yrs, p=0.34), gender (36 vs. 46% female, p=0.50), performance status (78 vs. 79% ECOG 0, p=0.98), histologic grade (86 vs. 77% grade 3, p=0.49), positive resection margins (14 vs. 29%, p=0.26), lymph node involvement (71 vs. 79%, p=0.54), median tumor diameter (4.0 vs. 4.3 cm, p=0.64), and proportion receiving radiotherapy (57 vs. 42%, p=0.31). PG patients received a median of 5.5 cycles (IQR, 3.3-6.0) of platinum chemotherapy, with 10 patients (71%) receiving cisplatin-based regimens and 4 (29%) receiving oxaliplatin-based regimens. PG patients experienced significantly longer median survival (19.1 months, 95% CI 12.8-25.4) compared to NPG patients (9.8 months, 95% CI 7.3-12.4) (p=0.024). Conclusions: Addition of a platinum agent to adjuvant regimens for resected PASC may improve survival among these high risk patients, though collaborative prospective investigation is needed.

show abstract

“…On the other hand, our group previously demonstrated a survival benefit with the use of chemoradiation therapy following resection in patients with PASC (10). Additional investigations of the efficacy of adjuvant chemoradiation are limited to anecdotal studies (6)(7)(8)14,(18)(19)(20).…”

Section: Original Articlementioning

confidence: 99%

“…Additional data were obtained in regard to potential prognostic factors identified in previously published reports (4)(5)(6)(7)(8)(10)(11)(12)(13)(14)(15)(18)(19)(20). Patient-specific variables included age, sex, and ECOG performance status.…”

Section: Data Collectionmentioning

confidence: 99%

Efficacy of Platinum Chemotherapy Agents in the Adjuvant Setting for Adenosquamous Carcinoma of the Pancreas

Dholakia

Wild

Fan

et al. 2013

Journal of the American Society of Cytopathology

View full text Add to dashboard Cite

Pancreatic adenosquamous carcinoma with 7‐year survival: A case report and literature review

Cited by 7 publications

References 15 publications

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review

Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.

Efficacy of Platinum Chemotherapy Agents in the Adjuvant Setting for Adenosquamous Carcinoma of the Pancreas

Contact Info

Product

Resources

About